FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255655126> ?p ?o ?g. }

• W4255655126 endingPage "LBA9012" @default.
• W4255655126 startingPage "LBA9012" @default.
• W4255655126 abstract "LBA9012 Background: Elesclomol is an investigational first-in-class oxidative stress inducer that increases oxidative stress in cancer cells leading to mitochondria-induced apoptosis. Methods: Patients (pts) with Stage IV MM, no prior chemotherapy, LDH μ 2× ULN were randomized (1:1) to either 213 mg/m2 elesclomol in combination with 80 mg/m2 paclitaxel (ELPAC) or 80 mg/m2 paclitaxel alone (P); both were given weekly ×3 followed by 1 week rest until disease progression. Pts were stratified by prior non-cytotoxic treatment, M1 grade, and LDH. The primary endpoint was PFS with >90% power to detect a 2-month improvement. The primary PFS analysis was planned once all pts had been enrolled and at least 164 PFS events had occurred. Results: 651 pts were enrolled between September 2007 and February 2009. Prognostic factors were generally well balanced. PFS analysis was based on investigator assessment of 411 pts (219 events). Median PFS was 3.5 m (95% CI 2.7–3.7) in ELPAC and 1.9 m (95% CI 1.9–3.3) in P [HR 0.88; 95% CI 0.67–1.16, p=0.3695]. The median number of cycles was 3 in ELPAC and 2 in P. Safety analysis showed increased signals on ELPAC including increased ≥Gr 3 AEs (N=405, 32.8% vs. 23.5%), increased AEs leading to death (N=405, 3.5% vs <1%) and increased overall deaths (N=651, 80 vs 53; 80% censored). Most common AEs in ELPAC were fatigue (32.8%), alopecia (31.3%) and nausea (27.9%). Conclusions: There was an improvement in PFS in the ELPAC arm, but it did not achieve statistical significance. In February 2009, the study was halted based on the recommendation of the DMC to unblind the study after the DMC observed increased deaths on the ELPAC arm. The DMC could not determine whether the observed increased deaths were treatment related or not. Of note, in this analysis there were no specific target organ toxicities attributable to ELPAC that could explain the imbalance of deaths. OS data continues to be collected to determine if the observed imbalance in OS persists as the data mature. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Synta Synta Synta" @default.
• W4255655126 created "2022-05-12" @default.
• W4255655126 creator A5003292233 @default.
• W4255655126 creator A5060495866 @default.
• W4255655126 creator A5080450234 @default.
• W4255655126 creator A5083575212 @default.
• W4255655126 date "2009-06-20" @default.
• W4255655126 modified "2023-10-17" @default.
• W4255655126 title "Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM)" @default.
• W4255655126 doi "https://doi.org/10.1200/jco.2009.27.18s.lba9012" @default.
• W4255655126 hasPublicationYear "2009" @default.
• W4255655126 type Work @default.
• W4255655126 citedByCount "2" @default.
• W4255655126 countsByYear W42556551262016 @default.
• W4255655126 crossrefType "journal-article" @default.
• W4255655126 hasAuthorship W4255655126A5003292233 @default.
• W4255655126 hasAuthorship W4255655126A5060495866 @default.
• W4255655126 hasAuthorship W4255655126A5080450234 @default.
• W4255655126 hasAuthorship W4255655126A5083575212 @default.
• W4255655126 hasConcept C126322002 @default.
• W4255655126 hasConcept C143998085 @default.
• W4255655126 hasConcept C146357865 @default.
• W4255655126 hasConcept C151730666 @default.
• W4255655126 hasConcept C168563851 @default.
• W4255655126 hasConcept C2776694085 @default.
• W4255655126 hasConcept C2777292972 @default.
• W4255655126 hasConcept C71924100 @default.
• W4255655126 hasConcept C86803240 @default.
• W4255655126 hasConceptScore W4255655126C126322002 @default.
• W4255655126 hasConceptScore W4255655126C143998085 @default.
• W4255655126 hasConceptScore W4255655126C146357865 @default.
• W4255655126 hasConceptScore W4255655126C151730666 @default.
• W4255655126 hasConceptScore W4255655126C168563851 @default.
• W4255655126 hasConceptScore W4255655126C2776694085 @default.
• W4255655126 hasConceptScore W4255655126C2777292972 @default.
• W4255655126 hasConceptScore W4255655126C71924100 @default.
• W4255655126 hasConceptScore W4255655126C86803240 @default.
• W4255655126 hasIssue "18S" @default.
• W4255655126 hasLocation W42556551261 @default.
• W4255655126 hasOpenAccess W4255655126 @default.
• W4255655126 hasPrimaryLocation W42556551261 @default.
• W4255655126 hasRelatedWork W10318798 @default.
• W4255655126 hasRelatedWork W10880188 @default.
• W4255655126 hasRelatedWork W14781274 @default.
• W4255655126 hasRelatedWork W15112652 @default.
• W4255655126 hasRelatedWork W16661828 @default.
• W4255655126 hasRelatedWork W17488553 @default.
• W4255655126 hasRelatedWork W19998997 @default.
• W4255655126 hasRelatedWork W20837101 @default.
• W4255655126 hasRelatedWork W21201042 @default.
• W4255655126 hasRelatedWork W21804091 @default.
• W4255655126 hasVolume "27" @default.
• W4255655126 isParatext "false" @default.
• W4255655126 isRetracted "false" @default.
• W4255655126 workType "article" @default.